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Abstract Photodynamic therapy (PDT) is a clinically effective
cancer treatment. For human promyelocytic leukemia HL-60
cells, cleavage of pro-caspase-3 (CPP32/Yama/apopain) into its
proteolytically active subunits rapidly follows the photodynamic
treatment of these cells with cytotoxic levels of the photo-
sensitizer benzoporphyrin derivative monoacid ring A and visible
light. Cleavage of a recently identified cytosolic 45 kDa protein,
DNA fragmentation factor (DFF), is required for endonuclease
activation leading to DNA fragmentation. In the present study,
DFF was rapidly processed following PDT. Overexpression of
the anti-apoptotic Bcl-XL gene in HL-60 cells prevented PDT-
induced caspase activation, DFF cleavage and DNA fragmenta-
tion. These results demonstrate for the first time an example of
chemotherapeutic drug-induced activation of DFF and its
regulation by Bcl-XL.
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1. Introduction
It is now established that the degradation of key cellular
substrates by caspase family proteases is fundamental to the
apoptotic process [1]. The most intensively studied of these
proteases, caspase-3 (CPP32/Yama/apopain), resides in the
cytosolic fraction of cells as a zymogen and is proteolytically
activated in cells undergoing apoptosis [2^4]. Caspase-3 sub-
strates include poly(ADP-ribose) polymerase (PARP) [3], ster-
ol regulatory element binding proteins [5], the U1-associated
70 kDa protein [1], and the catalytic subunit of DNA-depend-
ent protein kinase (DNA-PKCS) [1]. Lui et al. [6] recently
identi¢ed a protein, DNA fragmentation factor (DFF), which
is required for the initiation of endonuclease-mediated DNA
fragmentation and can be directly activated by caspase-3 in
vitro [6]. DFF is a cytosolic factor consisting of 40 kDa and
45 kDa subunits, of which the 45 kDa portion is cleaved into
smaller polypeptides by caspase-3 [6]. This observation di-
rectly links caspase-3 activation in apoptotic cells with DNA
fragmentation through the activation of DFF [6]. Thus, DFF
serves as a component in the executioner phase of apoptosis
but does not, to date, exhibit any proteolytic characteristics
[6].
Bcl-X functions as a Bcl-2-independent regulator of apop-
tosis [7]. Boise et al. demonstrated that alternative splicing
results in two distinct Bcl-X mRNA species [7]. The protein
product of the larger mRNA, Bcl-XL, encodes a protein com-
parable in function to the anti-apoptotic proto-oncogene Bcl-
2 [7]. The second mRNA species, Bcl-XS, encodes a protein
that promotes apoptotic activity [7]. Bcl-XL can form ion
channels upon insertion into synthetic lipid vesicles or planar
lipid bilayers suggesting that Bcl-XL a¡ects cell survival by
in£uencing the permeability of the intracellular membranes
to which it is distributed [8]. Bcl-XL exists in both soluble
and membrane-bound forms [9]. In cells undergoing apopto-
sis, soluble Bcl-XL shifts to the membrane-bound form, pos-
sibly forming ion channels in mitochondria [9]. Bcl-XL pre-
vents apoptosis by limiting the availability of cytochrome c
(cyt c) in the cytosol [10]. In coimmunoprecipitation studies,
Bcl-XL associated with cyt c but not Bcl-XS [10]. However,
Bcl-XS can interfere with the binding of cyt c to Bcl-XL, there-
by promoting apoptosis [10]. In the apoptotic pathway, Bcl-
XL acts upstream of caspase-3 and overexpression of Bcl-XL
corresponds to an absence of caspase-3 activation in cells
treated with various chemotherapeutic agents [11^13].
Photodynamic therapy (PDT) is an approved treatment
modality for various types of malignancies and involves the
topical or systemic application of a photosensitizing agent
followed by illumination with a speci¢c wavelength of light
[14]. Photoactivation of the chlorin-type photosensitizer, ben-
zoporphyrin derivative monoacid ring A (BPD-MA), eradi-
cates tumor cells through the generation of reactive oxygen
intermediates [15]. BPD-MA accumulates at higher levels in
leukemic cells as compared to normal blood mononuclear
cells [15,16]. In vitro experiments have shown that photoacti-
vation of BPD-MA can selectively deplete leukemic cells while
relatively sparing normal hematopoietic progenitor cells
[16,17].
Treatment of human promyelocytic leukemia HL-60 cells
with BPD-MA and light rapidly produces DNA fragmenta-
tion and apoptotic cell death [18]. Caspase-3, but not caspase-
1, activation followed by PARP and DNA-PKCS degradation
occurred in HL-60 cells treated with BPD-MA and light [18].
The present report demonstrates two novel ¢ndings: (1) DFF
is rapidly activated following PDT and (2) Bcl-XL overexpres-
sion in HL-60 cells or pretreatment with the caspase-3 inhib-
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itor Z-DEVD-fmk prevents PDT-mediated DFF activation,
caspase-3 activity and DNA fragmentation.
2. Materials and methods
2.1. Reagents
Liposomally formulated BPD-MA was provided by QLT Photo-
Therapeutics Inc. (Vancouver, BC). All antibodies, with the exception
of rabbit anti-DFF, were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA). The DFF antibody was kindly provided by
Dr. Xiaodong Wang (University of Texas Southwestern Medical
School, Dallas, TX). All other drugs and chemicals, unless speci¢ed,
were from Sigma Chemical Co. (St. Louis, MO).
2.2. Cell culture
The transfected human promyelocytic leukemia HL-60/neo and
HL-60/Bcl-XL cell lines were generously provided by Dr. Kapil Bhalla
(Emory University School of Medicine, Atlanta, GA). Detailed meth-
ods used to generate these clones have been described [11]. Bcl-2 and
Bax levels were comparable in both transfectants [11]. Cells were
maintained in RPMI 1640 medium supplemented with 10% heat-in-
activated fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM sodium
pyruvate, 1 mM HEPES, penicillin (100 U/ml) and streptomycin (100
Wg/ml) (Gibco BRL, Burlington, Ont.) and G418 (1 mg/ml) (Genet-
icin; Life Technologies Inc., Grand Island, NY).
2.3. Photoactivation of BPD-MA
For photoinactivation studies, cells were incubated for a total of 60
min at 37‡C with or without BPD-MA (0^100 ng/ml) in RPMI me-
dium with 10% FBS. For caspase-3 inhibition studies, Z-Asp-Glu-Val-
Asp-£uoromethylketone (Z-DEVD-fmk) (20 WM) (Enzyme Systems
Prod., Dublin, CA) was added to cells during the ¢nal 30 min of
the BPD-MA incubation period. Cells were then exposed to £uores-
cent red light (620^700 nm) delivered at a rate of 5.6 mW/cm2 to give
a total dose of 2 J/cm2. Following light treatment, cells were main-
tained at 37‡C until further analysis.
2.4. Preparation of cellular protein extracts
To obtain cytosolic extracts, cells were treated 1 h after PDT in 1 ml
of lysis bu¡er (1% Nonidet P-40 detergent (NP-40), 20 mM Tris, pH
8, 137 mM NaCl, 10% glycerol) supplemented with 1 mM phenyl-
methylsulfonyl £uoride, aprotinin (0.15 U/ml), and 1 mM sodium
orthovanadate for 20 min on ice as previously described [18].
2.5. Protease assay
A cell-free protease assay was performed by incubating 10 Wg of cell
lysate protein in 150 Wl of reaction bu¡er (1% NP-40, 20 mM Tris, pH
7.5, 137 mM NaCl, 10% glycerol) containing 100 WM of the caspase-3
substrate (acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin (Ac-
DEVD-AMC)) (Calbiochem, Cambridge, MA) in 96-well microtiter
plates [18]. Lysates were incubated at 37‡C for 16 h and cleaved
substrate £uorescence levels were determined using a CytoFluor
2350 (PerSeptive Biosystems, Ont., Canada) set at excitation and
emission wavelengths of 380 nm and 460 nm, respectively.
2.6. Immunoblot analysis
Detergent soluble proteins (30 Wg) were separated by SDS-PAGE in
12% acrylamide gels, under reducing conditions followed by Western
blotting as described [18]. Membranes were incubated for 45 min
using the following polyclonal antibodies at 1 Wg/ml: goat anti-
PARP, goat anti-CPP32, rabbit anti-DFF or rabbit anti-Bcl-XS=L.
Membranes were probed with horseradish peroxidase-labelled anti-
goat IgG or anti-rabbit IgG antibodies (1:5000) in PBS, 0.05% Tween
20, 5% (w/v) skim milk powder for 30 min at room temperature.
Proteins were detected using the enhanced chemiluminescence detec-
tion system (Amersham, Arlington Heights, IL) and bands visualized
by autoradiography.
2.7. Analysis of DNA fragmentation
Propidium iodide (PI) £uorescence analysis and £ow cytometry
were utilized to quantitate subdiploid amounts of cellular DNA as
described elsewhere [18^20]. A 3 h post-treatment timepoint was uti-
lized since there was little change in the level of DNA fragmentation
at later timepoints (not shown).
3. Results and discussion
3.1. Overexpression of Bcl-XL blocks caspase-3-like protease
activity and DNA fragmentation
We have previously demonstrated that caspase-3 activation,
but not caspase-1 activation, occurs in HL-60 cells treated
with PDT [18]. Cytosolic extracts prepared from HL-60 cells
with overexpression of Bcl-XL exhibited minimal cleavage of
the caspase-3 substrate (Ac-DEVD-AMC) in contrast to the
HL-60/neo cells treated with the same level of BPD-MA and
light, thereby providing support that Bcl-XL overexpression
blocks caspase-3-like activity (Fig. 1A).
HL-60/neo and HL-60/Bcl-XL cells were also assessed for
the presence of DNA fragmentation 3 h after photoactivation
of BPD-MA (Fig. 1B). The vast majority of HL-60/neo cells
treated with BPD-MA and light exhibited DNA fragmenta-
tion as compared to untreated cells or cells exposed to BPD-
MA alone. However, there was no evidence of a change in
DNA fragmentation levels in HL-60/Bcl-XL cells treated with
BPD-MA and light at 3 h after photoactivation.
3.2. DFF is rapidly processed following PDT
Since levels of caspase-3-like activity as determined by the
protease assay directly corresponded to subsequent levels of
DNA fragmentation, our next aim was to examine possible
links between these two events. Recent experiments by Liu et
al. [6] identi¢ed a novel protein (DFF) in staurosporine-
treated HeLa cells that is proteolytically cleaved during apop-
tosis. It was demonstrated that caspase-3 could cleave this
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Fig. 1. Overexpression of Bcl-XL blocks (A) PDT-induced DEVD-
ase activity and (B) DNA fragmentation. A: At 1 h after treatment,
lysates for HL-60/neo (F) or HL-60/Bcl-XL (E) cells were prepared
and assayed for their capacity to cleave the £uorescently labelled
caspase-3 substrate (Ac-DEVD-AMC). Cytosolic extracts were pre-
pared from cells treated with light (control), BPD-MA (100 ng/ml)
or BPD-MA (100 ng/ml) and light (2 J/cm2) (PDT). B: HL-60/neo
(F) and HL-60/Bcl-XL (E) cells were assessed for DNA fragmenta-
tion by PI staining 3 h after the indicated treatments.
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protein into active subunits that were required to induce DNA
fragmentation in isolated cell nuclei [6].
Wild type HL-60 cell lysates were prepared at 5, 15, 30 or
60 min following PDT. Immunoblot analysis showed that pro-
caspase-3 cleavage was evident within 5 min after PDT (Fig.
2). Furthermore, virtually all DFF was processed by 15 min
post-PDT, whereas PARP was not completely cleaved until 30
min post-PDT (Fig. 2). The earlier cleavage of DFF by cas-
pase-3 may be attributable to the cytosolic localization of
DFF and to the nuclear localization of PARP. Our observa-
tion that DFF was cleaved in PDT-treated cells undergoing
apoptosis is consistent with that of Liu et al. [6] in which
staurosporine was used as the pro-apoptotic stimulant in
HeLa cells.
Treatment of the HL-60 cells with the caspase-3 inhibitor,
Z-DEVD-fmk, prior to light activation of BPD-MA, pre-
vented DFF and PARP cleavage (Fig. 3). The observation
that Z-DEVD-fmk blocks PARP cleavage is consistent with
results obtained by other investigators [2^4]. Our DFF results
for HL-60 cells treated with PDT support evidence by Liu et
al. suggesting that DFF is a substrate of caspase-3 [6]. Upon
activation, it is believed that DFF may either translocate into
the nucleus or interact with speci¢c proteins on the nuclear
envelope to trigger a signaling cascade resulting in endonu-
clease activation [6]. Further experiments are required in order
to determine the mechanism of DFF-mediated endonuclease
activation.
3.3. Overexpression of Bcl-XL blocks PDT-induced caspase-3,
PARP and DFF cleavage
To further examine upstream events regulating PDT-in-
duced DFF activation, the role of the anti-apoptotic Bcl-XL
proto-oncogene was assessed. The status of Bcl-XL, caspase-3,
PARP and DFF in cytosolic extracts from PDT-treated cells
was determined by Western immunoblotting. A minimal level
of Bcl-XL expression was detected in the HL-60/neo cells as
compared to the HL-60/Bcl-XL transfectants (Fig. 4). No ap-
parent cleavage or size alteration of Bcl-XL was observed in
neither the PDT-treated HL-60/neo or HL-60/Bcl-XL cells.
Following light activation of BPD-MA, caspase-3, PARP
and DFF were cleaved in the HL-60/neo cell lysates but not
in the HL-60/Bcl-XL cell extracts (Fig. 4). These results indi-
cate that DFF activation by PDT is subject to Bcl-XL regu-
lation.
Previous studies have shown that Bcl-XL localizes to the
outer mitochondria membrane and prevents the activation
of caspase-3 in response to a variety of apoptotic signals by
blocking the release of cyt c from mitochondria [10]. HL-60
cells undergoing apoptosis exhibit an increase of cytosolic cyt
c levels and a corresponding decrease of mitochondrial cyt c
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Fig. 4. Overexpression of Bcl-XL in HL-60 cells blocks the cleavage
of pro-caspase-3, PARP, and DFF induced by treatment with BPD-
MA and light. Cells were lysed 1 h after light irradiation. Cell ly-
sates were separated by SDS-PAGE followed by Western immuno-
blotting. Cells were treated with light (control), BPD-MA (100 ng/
ml) or BPD-MA (100 ng/ml) plus light (2 J/cm2) (PDT).
Fig. 3. DFF is cleaved by a caspase-3-like protease. At 1 h after
PDT, cell lysates were prepared. Proteins were separated by SDS-
PAGE followed by Western immunoblotting using anti-DFF or
anti-PARP antibodies. HL-60 cells were treated with light (control),
BPD-MA (100 ng/ml), BPD-MA (100 ng/ml) and light (2 J/cm2)
(PDT) or BPD-MA (100 ng/ml) and Z-DEVD-fmk (20 WM) and
light (2 J/cm2) (PDT+Z-DEVD-fmk).
Fig. 2. DFF is rapidly cleaved following PDT. Following PDT, wild
type HL-60 cells were lysed at the indicated timepoints. Cell lysates
were separated by SDS-PAGE followed by Western immunoblotting
using anti-caspase-3 (p12), anti-DFF, or anti-PARP (p25) antibod-
ies.
D.J. Granville et al./FEBS Letters 422 (1998) 151^154 153
levels [21]. By regulating the release of cyt c, Bcl-XL may
impede apoptotic events by blocking caspase-3 activation
and subsequent DFF activation which leads to endonu-
clease-mediated DNA fragmentation [21,22].
The ¢ndings in the present study demonstrate that PDT
induces the activation of DFF through caspase-3 and that
these processes are subject to Bcl-XL regulation. It has pre-
viously been demonstrated that Bcl-XL can bind to cyto-
chrome c thereby blocking its release from the mitochondria
[10] and that cyt c is necessary for caspase-3 activation [21^
23]. Cyt c has also been shown to bind to Apaf-1 (apoptotic
protease activating factor-1), a recently discovered human ho-
molog of the nematode death-regulating CED-4 gene [23]. An
interesting hypothesis is that cyt c may activate caspase-3 by
disrupting the mitochondrial complex between Bcl-XL and
Apaf-1 [23]. Following the application of a pro-apoptotic
stimuli such as PDT, cyt c may bind to Bcl-XL thereby releas-
ing Apaf-1 for caspase-3 processing. Thus, increasing Bcl-XL
may o¡set the e¡ects of any increase in cyt c release by sup-
pressing its binding capabilities to Apaf-1 thereby blocking
further caspase-3 processing and DFF activation. The mech-
anisms by which DFF activates endonucleases involved in
DNA fragmentation will be explored in future studies.
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